Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration

Boyer, David S.; Antoszyk, Andrew N.; Awh, Carl C.; Bhisitkul, Robert B.; Shapiro, Howard; Acharya, Nisha R.

doi:10.1016/j.ophtha.2006.10.045

Cited by 374 publications

(294 citation statements)

References 5 publications

Supporting

Mentioning

247

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have shown variable outcomes associated with anti-VEGF therapy for this condition. 1,[6][7][8][9][10][11][12][13][14][15][16][17][18][19] In 2012, Introini et al 13 studied 132 eyes with vPED or retinal angiomatous proliferation lesions treated with PDT, PDT and intravitreal corticosteroid (IVT),or anti-VEGF therapy over 10 years. At 12 months after treatment, there was marked worsening of vision for eyes treated with PDT or PDT and IVT, and mild decreased vision for eyes treated with anti-VEGF injections despite favorable anatomic outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…1,7,8 The ANCHOR and MARINA studies demonstrated improved vision in eyes receiving monthly ranibizumab injections (RI). [9][10][11] The HABOR Study reported equivalent visual and anatomical outcomes between high dose (2.0 mg) and conventional dose (0.5 mg) of ranibizumab for treatment of exudative AMD at 12 months. 12 Stratification of lesion subtypes was not a part of these studies; therefore, its applicability to the more difficult-to-treat subtypes of neovascular AMD such as vPED is unknown.…”

Section: Introductionmentioning

confidence: 99%

“…Recent studies evaluated the outcomes of ranibizumab for treating vPED due to AMD, but not comparing the results of various doses of ranibizumab. 1,[6][7][8][9][10][11][12][13][14][15][16][17][18][19] Our prospective study addressed the benefits and risks of 2.0 vs 0.5 mg ranibizumab for treating vPED due to AMD on a monthly as well as pro-re nata (PRN) basis for up to 12 months.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration

Chan

Abraham

Sarraf

et al. 2014

Eye

View full text Add to dashboard Cite

Summary statement Intravitreal high dose (2 mg) ranibizumab may lead to quicker resolution of choroidal neovascularization (CNV) and associated retinal pigment epithelial detachment in eyes with exudative age-related macular degeneration, although it may possibly correlate with RPE tears in certain cases. Purpose This prospective study compared the outcomes of 0.5 vs 2.0 mg intravitreal ranibizumab injections (RI) for treating vascularized pigment epithelial detachment (vPED) due to age-related macular degeneration. Methods Patients with vPED were randomized to receive 2.0 vs 0.5 mg RI monthly for 12 months or for 4 months and then repeated on a pro-re nata basis. Optical coherence tomography, fundus photography, and fluorescein and indocyanine-green angiography were obtained at baseline and subsequent specific intervals. Outcome measures were best-corrected standardized visual acuities, central 1-mm thickness, surface area (SA), greatest linear diameter (GLD), heights (PED and CNV), and amount of subretinal fluid (SRF) and cystoid macular edema (CME). Results Both groups yielded reductions of the central 1-mm thickness, PED and CNV SA and PED height and GLD, SRF, and CME. Vision improvement and reduction in SRF and PED height occurred earlier for eyes receiving the 2.0 mg dose. Cataract progression was similar but RPE tears developed more often with the 2.0 mg dose. Conclusions There were similar visual and anatomical outcomes at the end of the study; however, the higher dose yielded more rapid reductions and more complete resolution of the PED, although there was possible increased tendency for an RPE tear with the higher dose.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration

Chan

Abraham

Sarraf

et al. 2014

Eye

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7][8][9][10] The ratio of treating CNV with anti-vascular endothelial growth factor (anti-VEGF) is hindering angiogenesis factor being produced by retinal pigment epithelium (RPE) and retinal photoreceptors, and hence avoiding initiating and supporting the growth of abnormal CNV. 11,12 The use of indocyanine green angiography (ICGA) in diagnosing CSCR patients has improved our understanding in the pathogenesis of CSCR.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy

Smretschnig

Hagen

Glittenberg

et al. 2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate the results of indocyanine green angiography (ICGA)-guided verteporfin photodynamic therapy (PDT) with half-fluence rate combined with intravitreal application of anti-VEGF in treating choroidal neovascularization (CNV) in chronic central serous chorioretinopathy (CSCR). Patients and methods In this retrospective cohort study 17 consecutive patients with secondary CNV due to chronic CSCR had their diagnosis verified with fluorescein angiography (FA) and ICGA at baseline. All eyes received either intravitreal ranibizumab (IVR) or bevacizumab (IVB). On the consecutive day following the initial IVR/IVB treatment, ICGAguided verteporfin (6 mg/m 2 ) PDT with halffluence rate (25 J/cm 2 ) was performed on every patient. IVR or IVB was rescheduled on a pro re nata regimen. Main outcome measures were changes in visual acuity (VA) according to the ETDRS letter score and changes in the central foveal thickness (CFT). Results Best-corrected VA at baseline was 65.6 letters (±6.7; n = 17) according to the ETDRS letter score. At 12 months, mean ETDRS letter score improved to 71.2 letters (P = 0.34). CFT was 309 μm and decreased to 216 μm at month 12 control (P = 0.0004). Nine eyes (52.9%) received additional treatment with IVR/IVB due to recurrence of subretinal fluid, with an overall mean number of IVR/IVB treatment of 1.8 ± 3.6 per patient with no systemic side effects during 12 months' follow-up. Conclusions IVR or IVB combined with ICGA-guided half-fluence PDT with verteporfin is effective in treating CNV in chronic CSCR, with choroidal hyperpermeability in ICGA, resulting in stable vision and significant reduction of CFT.

show abstract

“…These types of ceiling and floor effects have been reported for treatment outcomes associated with both diabetic maculopathy and age-related macular degeneration. 1,23 The duration of oedema may be an important determinant of final visual outcomes, but this factor was not analysed directly in the current study. Nevertheless, the poorer results in year 3-5 may serve as a surrogate marker of chronicity of disease.…”

Section: Eyementioning

confidence: 99%

Five-year visual outcome following laser photocoagulation of diabetic macular oedema

Jyothi

Sivaprasad

2011

Eye

View full text Add to dashboard Cite

Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration

Cited by 374 publications

References 5 publications

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration

Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy

Five-year visual outcome following laser photocoagulation of diabetic macular oedema

Contact Info

Product

Resources

About